InnoCare Pharma Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

InnoCare Pharma yıllık ortalama 25.7% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 31.7% annual. Gelirler yılda ortalama 38.2% oranında büyüyor .

Anahtar bilgiler

25.7%

Kazanç büyüme oranı

65.5%

EPS büyüme oranı

Biotechs Sektör Büyümesi	11.0%
Gelir büyüme oranı	38.2%
Özkaynak getirisi	-5.7%
Net Marj	-41.8%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

InnoCare Pharma nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

SZSC:9969 Gelir, gider ve kazançlar (CNY Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 24	899	-376	557	823
30 Jun 24	781	-471	520	817
31 Mar 24	715	-761	560	794
31 Dec 23	739	-631	551	757
30 Sep 23	721	-584	598	723
30 Jun 23	757	-867	625	732
31 Mar 23	696	-781	606	660
31 Dec 22	625	-887	614	649
30 Sep 22	503	-987	562	605
30 Jun 22	1,187	-296	516	815
31 Mar 22	1,111	-78	475	759
31 Dec 21	1,043	-65	437	722
30 Sep 21	982	60	337	678
30 Jun 21	102	-266	286	356
31 Mar 21	52	-329	222	380
31 Dec 20	1	-391	158	403
30 Sep 20	1	-1,853	131	382
30 Jun 20	1	-2,155	105	349
31 Mar 20	1	-2,148	86	281
31 Dec 19	1	-2,141	67	213
30 Sep 19	2	-742	51	190
30 Jun 19	2	-592	29	181
31 Mar 19	2	-571	24	165
31 Dec 18	2	-550	18	150
31 Dec 17	0	-342	15	63

Kaliteli Kazançlar: 9969 şu anda kârlı değil.

Büyüyen Kar Marjı: 9969 şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 9969 kârlı değildir, ancak son 5 yılda zararlarını yılda 25.7% oranında azaltmıştır.

Büyüme Hızlandırma: 9969 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: 9969 kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 7.1% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: 9969 hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -5.74% ) sahiptir.

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/24 17:50
Gün Sonu Hisse Fiyatı	2024/12/24 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

InnoCare Pharma Limited 17 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Peng Zou	China International Capital Corporation Limited
Tan Huan Gan	Citic Securities Co., Ltd.
Shitong Han	Citic Securities Co., Ltd.

InnoCare Pharma Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Third quarter 2024 earnings released: CN¥0.007 loss per share (vs CN¥0.062 loss in 3Q 2023)

InnoCare Pharma Limited to Report Q3, 2024 Results on Nov 12, 2024

Second quarter 2024 earnings released: CN¥0.08 loss per share (vs CN¥0.19 loss in 2Q 2023)

InnoCare Pharma Limited to Report First Half, 2024 Results on Aug 21, 2024

First quarter 2024 earnings released: CN¥0.08 loss per share (vs CN¥0.007 loss in 1Q 2023)

InnoCare Pharma Limited to Report Q1, 2024 Results on May 14, 2024

Recent updates

Third quarter 2024 earnings released: CN¥0.007 loss per share (vs CN¥0.062 loss in 3Q 2023)

InnoCare Pharma Limited Announces Phase II Clinical Study of Icp-488 for the Treatment of Moderate-To-Severe Plaque Psoriasis

InnoCare Pharma Announces Phase II Study Results of TYK2 Inhibitor ICP-488 Meet Primary Endpoint in Psoriasis Patients

InnoCare Pharma Limited to Report Q3, 2024 Results on Nov 12, 2024

InnoCare Pharma Limited Announces Board and Committee Changes

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

InnoCare Pharma Limited Announces End of Phase 2 Meeting with the U.S. Food and Drug Administration Regarding the Clinical Development of Orelabrutinib for the Treatment of Multiple Sclerosis

Second quarter 2024 earnings released: CN¥0.08 loss per share (vs CN¥0.19 loss in 2Q 2023)

InnoCare Pharma Announces First Subject Dosed in Clinical Trial of TYK2 Inhibitor ICP-332 in the U.S

InnoCare Pharma Limited to Report First Half, 2024 Results on Aug 21, 2024

InnoCare Pharma Announces the Acceptance of Biologics License Application for Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Adult Patients in China

InnoCare Pharma Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

First quarter 2024 earnings released: CN¥0.08 loss per share (vs CN¥0.007 loss in 1Q 2023)

InnoCare Pharma Limited to Report Q1, 2024 Results on May 14, 2024

Full year 2023 earnings released: CN¥0.37 loss per share (vs CN¥0.60 loss in FY 2022)

InnoCare Pharma Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib

InnoCare Pharma Limited Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China

InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended 31 December 2023

InnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK Inhibitor Zurletrectinib in China

InnoCare Pharma Announces Clearance of Clinical Trial of BCL2 Inhibitor ICP-248 by U.S. FDA

New minor risk - Profitability

InnoCare Pharma Appoints Xin Fu as Chief Financial Officer

InnoCare Pharma Announces Latest Data of Oncology Pipelines Presented at the 65th Annual Meeting of ASH

Third quarter 2023 earnings released: CN¥0.062 loss per share (vs CN¥0.28 loss in 3Q 2022)

New minor risk - Profitability

InnoCare Pharma Announces First Patient Dosed in the Phase III Registrational Trial of Orelabrutinib for the Treatment of ITP in China

Innocare Pharma Limited Announces the Appointment of Dandan Dong as Independent Non-Executive Director

InnoCare Pharma Limited (SEHK:9969) commences an Equity Buyback Plan for 149,967,323 shares, representing 8.5% of its issued share capital, under the authorization approved on June 2, 2023.

InnoCare Pharma Limited (SEHK:9969) commences an Equity Buyback Plan for 149,967,323 shares, representing 8.5% of its issued share capital, under the authorization approved on June 2, 2023.

InnoCare Pharma Announces Approval of Clinical Trial of SHP2 Inhibitor ICP-189 in Combination with EGFR Inhibitor Furmonertinib

InnoCare Announces Study Result of Orelabrutinib in Patients with r/r MZL Published by American Journal of Hematology

Second quarter 2023 earnings released: CN¥0.19 loss per share (vs CN¥0.24 loss in 2Q 2022)

Innocare Pharma Limited Announces Board Changes

InnoCare Pharma Limited to Report First Half, 2023 Results on Aug 30, 2023

First quarter 2023 earnings released: CN¥0.01 loss per share (vs CN¥0.16 loss in 1Q 2022)

No longer forecast to breakeven

Full year 2022 earnings released: CN¥0.60 loss per share (vs CN¥0.047 loss in FY 2021)

Forecast breakeven date pushed back to 2025

InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended 31 December 2022

InnoCare Pharma Limited Announces the Latest Clinical Result of FGFR Inhibitor Gunagratinib (ICP-192) for the Treatment of Cholangiocarcinoma Was Presented At 2023 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium

Now 27% undervalued

InnoCare Pharma Limited Announces Approval of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong

No longer forecast to breakeven

InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Orelabrutinib in Combination with Tafasitamab + Lenalidomide in China

InnoCare Pharma Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Mantle Cell Lymphoma in Singapore

Third quarter 2022 earnings released: CN¥0.28 loss per share (vs CN¥0.17 profit in 3Q 2021)

Less than half of directors are independent

InnoCare Pharma Limited to Report Nine Months, 2022 Results on Nov 11, 2022

InnoCare Announces First Adolescent Patient Dosed in Clinical Trial of pan-TRK Inhibitor ICP-723 in China

InnoCare Pharma Limited has completed a Follow-on Equity Offering in the amount of CNY 2.672498 billion.

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in China

InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China

InnoCare Pharma Limited Announces Priority Review of Orelabrutinib for the Treatment of R/R MZL by NMPA

InnoCare Pharma Limited Announces Priority Review of Orelabrutinib for the Treatment of R/R MZL by NMPA

No longer forecast to breakeven

InnoCare Pharma Announces the Acceptance of the Biologics License Application for Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong

InnoCare Pharma and Keymed Biosciences Jointly Announce Approval of Clinical Trial of CCR8 Monoclonal Antibody CM369

First half 2022 earnings released: CN¥0.31 loss per share (vs CN¥0.16 loss in 1H 2021)

InnoCare Pharma Limited Provides Earnings Guidance for the Nine Months Ended 30 September 2022

InnoCare Pharma Announces Acceptance of Supplemental New Drug Application for Orelabrutinib in Relapsed or Refractory Marginal Zone Lymphoma in China

Innocare Pharma Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

InnoCare Pharma Limited Announces First Subject Dosed in Clinical Trial of TYK2 JH2 Allosteric Inhibitor ICP-488 in China

Innocare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Boao Hope City’s Early Access Program

InnoCare Pharma Limited Announces Approval of Clinical Trial of Novel Targeted Protein Degrader Icp-490 in China

InnoCare Pharma Limited Announces First Patient Dosed in Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 in China

Innocare Announces Approval to Conduct A Phase II Clinical Trial of Tafasitamab in Combination with Lenalidomide in China

Forecast breakeven date pushed back to 2024

Less than half of directors are independent

InnoCare Presents Pre-Clinical Data of ICP-723 at AACR Annual Meeting 2022